Tag Archives: NOACs

With the number of patients with atrial fibrillation (AF) set to double by 2050, appropriate anticoagulation for this growing condition was highlighted in a special session at the meeting – a ‘State of The Art Lecture’. Professor Stefan H Hohnloser (JW Goethe University, Frankfurt, Germany) described how stroke in Europe costs an estimated €38 billion per year, with 20% attributable to AF. Yet a decade ago, around 40% of AF patients did not receive appropriate anticoagulation. Of those receiving therapy, only around 50% of time in therapeutic range (TTR) is seen. With this in mind, novel oral anticoagulants (NOACs) are non-inferior to

A website for AF patients AFib Matters (www.afibmatters.org) was introduced by the EHRA at the meeting. The site outlines what AF is, symptoms, complications, types of drugs, and the need for stroke prevention. A section is devoted to frequently asked questions. Professor Gregory YH Lip, who was Chairman of the Task Force responsible for the development of the website, said: “Patients with AF often have questions or misconceptions about their condition, such as whether they can travel, should they avoid certain foods, what can interact with their medication, and what is the risk of treatments. All of these questions are answered on the webs